Annual Total Liabilities
$8.49 M
+$504.50 K+6.32%
31 December 2023
Summary:
Oncolytics Biotech annual total liabilities is currently $8.49 million, with the most recent change of +$504.50 thousand (+6.32%) on 31 December 2023. During the last 3 years, it has risen by +$963.00 thousand (+12.80%). ONCY annual total liabilities is now -43.92% below its all-time high of $15.13 million, reached on 31 December 2019.ONCY Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$11.25 M
+$1.21 M+12.04%
30 September 2024
Summary:
Oncolytics Biotech quarterly total liabilities is currently $11.25 million, with the most recent change of +$1.21 million (+12.04%) on 30 September 2024. Over the past year, it has dropped by -$1.30 million (-10.39%). ONCY quarterly total liabilities is now -25.63% below its all-time high of $15.13 million, reached on 31 December 2019.ONCY Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ONCY Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +6.3% | -10.4% |
| 3 y3 years | +12.8% | +45.3% |
| 5 y5 years | +33.3% | +16.1% |
ONCY Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +12.8% | -10.4% | +59.0% |
| 5 y | 5 years | -43.9% | +33.3% | -25.6% | +59.0% |
| alltime | all time | -43.9% | +5125.1% | -25.6% | +1780.7% |
Oncolytics Biotech Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $11.25 M(+12.0%) |
| June 2024 | - | $10.04 M(+15.2%) |
| Mar 2024 | - | $8.72 M(+2.7%) |
| Dec 2023 | $8.49 M(+6.3%) | $8.49 M(-32.4%) |
| Sept 2023 | - | $12.56 M(+71.1%) |
| June 2023 | - | $7.34 M(+3.7%) |
| Mar 2023 | - | $7.08 M(-11.3%) |
| Dec 2022 | $7.98 M(+4.0%) | $7.98 M(+3.3%) |
| Sept 2022 | - | $7.72 M(+5.1%) |
| June 2022 | - | $7.35 M(-2.7%) |
| Mar 2022 | - | $7.55 M(-1.5%) |
| Dec 2021 | $7.67 M(+2.0%) | $7.67 M(-1.0%) |
| Sept 2021 | - | $7.75 M(-2.2%) |
| June 2021 | - | $7.92 M(+5.1%) |
| Mar 2021 | - | $7.53 M(+0.2%) |
| Dec 2020 | $7.52 M(-50.3%) | $7.52 M(-2.0%) |
| Sept 2020 | - | $7.67 M(-1.3%) |
| June 2020 | - | $7.77 M(-0.9%) |
| Mar 2020 | - | $7.84 M(-48.2%) |
| Dec 2019 | $15.13 M(+137.7%) | $15.13 M(+56.1%) |
| Sept 2019 | - | $9.69 M(+10.5%) |
| June 2019 | - | $8.77 M(+8.8%) |
| Mar 2019 | - | $8.06 M(+26.6%) |
| Dec 2018 | $6.37 M(-18.9%) | $6.37 M(-9.6%) |
| Sept 2018 | - | $7.04 M(-4.0%) |
| June 2018 | - | $7.34 M(+1.0%) |
| Mar 2018 | - | $7.27 M(-7.4%) |
| Dec 2017 | $7.85 M(+160.0%) | $7.85 M(+250.8%) |
| Sept 2017 | - | $2.24 M(-12.1%) |
| June 2017 | - | $2.55 M(+1.4%) |
| Mar 2017 | - | $2.51 M(-16.8%) |
| Dec 2016 | $3.02 M(+54.6%) | $3.02 M(+41.2%) |
| Sept 2016 | - | $2.14 M(-0.6%) |
| June 2016 | - | $2.15 M(+9.2%) |
| Mar 2016 | - | $1.97 M(+0.8%) |
| Dec 2015 | $1.95 M(-32.8%) | $1.95 M(-20.0%) |
| Sept 2015 | - | $2.44 M(-1.0%) |
| June 2015 | - | $2.46 M(-26.9%) |
| Mar 2015 | - | $3.37 M(+16.0%) |
| Dec 2014 | $2.91 M(-48.5%) | $2.91 M(-1.7%) |
| Sept 2014 | - | $2.96 M(-14.0%) |
| June 2014 | - | $3.44 M(-21.4%) |
| Mar 2014 | - | $4.37 M(-22.5%) |
| Dec 2013 | $5.64 M(-23.0%) | $5.64 M(+18.5%) |
| Sept 2013 | - | $4.76 M(-8.0%) |
| June 2013 | - | $5.18 M(-6.5%) |
| Mar 2013 | - | $5.54 M(-24.5%) |
| Dec 2012 | $7.33 M | $7.33 M(+7.1%) |
| Sept 2012 | - | $6.84 M(+33.3%) |
| June 2012 | - | $5.13 M(-15.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $6.09 M(-4.4%) |
| Dec 2011 | $6.37 M(+154.8%) | $6.37 M(+90.1%) |
| Sept 2011 | - | $3.35 M(-22.5%) |
| June 2011 | - | $4.32 M(+79.6%) |
| Mar 2011 | - | $2.41 M(-3.7%) |
| Dec 2010 | $2.50 M(-37.7%) | $2.50 M(+42.6%) |
| Sept 2010 | - | $1.75 M(-48.8%) |
| June 2010 | - | $3.42 M(+18.6%) |
| Mar 2010 | - | $2.89 M(-28.0%) |
| Dec 2009 | $4.01 M(+9.0%) | $4.01 M(+37.6%) |
| Sept 2009 | - | $2.92 M(+5.0%) |
| June 2009 | - | $2.78 M(-18.0%) |
| Mar 2009 | - | $3.39 M(-8.0%) |
| Dec 2008 | $3.68 M(+30.2%) | $3.68 M(+39.8%) |
| Sept 2008 | - | $2.63 M(-35.2%) |
| June 2008 | - | $4.07 M(+51.5%) |
| Mar 2008 | - | $2.68 M(-5.1%) |
| Dec 2007 | $2.83 M(+19.2%) | $2.83 M(+22.2%) |
| Sept 2007 | - | $2.31 M(+3.7%) |
| June 2007 | - | $2.23 M(-9.6%) |
| Mar 2007 | - | $2.47 M(+4.1%) |
| Dec 2006 | $2.37 M(+49.6%) | $2.37 M(+5.4%) |
| Sept 2006 | - | $2.25 M(+22.2%) |
| June 2006 | - | $1.84 M(-0.6%) |
| Mar 2006 | - | $1.85 M(+17.0%) |
| Dec 2005 | $1.59 M(+73.3%) | $1.59 M(+0.6%) |
| Sept 2005 | - | $1.58 M(+14.1%) |
| June 2005 | - | $1.38 M(+18.0%) |
| Mar 2005 | - | $1.17 M(+28.0%) |
| Dec 2004 | $914.70 K(+14.8%) | $914.70 K(-24.3%) |
| Sept 2004 | - | $1.21 M(+50.8%) |
| June 2004 | - | $801.10 K(-51.1%) |
| Mar 2004 | - | $1.64 M(+105.5%) |
| Dec 2003 | $796.90 K(-10.8%) | $796.90 K(+6.4%) |
| Sept 2003 | - | $748.80 K(+25.1%) |
| June 2003 | - | $598.40 K(-13.1%) |
| Mar 2003 | - | $688.40 K(-23.0%) |
| Dec 2002 | $893.60 K(-54.2%) | $893.60 K(+33.9%) |
| Sept 2002 | - | $667.50 K(-18.7%) |
| June 2002 | - | $820.70 K(-17.2%) |
| Mar 2002 | - | $991.30 K(-49.2%) |
| Dec 2001 | $1.95 M(+68.1%) | $1.95 M(-4.2%) |
| Sept 2001 | - | $2.04 M(+57.2%) |
| June 2001 | - | $1.30 M(+36.0%) |
| Mar 2001 | - | $953.10 K(-17.9%) |
| Dec 2000 | $1.16 M(+615.1%) | $1.16 M(-28.3%) |
| Sept 2000 | - | $1.62 M(-2.5%) |
| June 2000 | - | $1.66 M(+73.7%) |
| Mar 2000 | - | $956.10 K |
| Dec 1999 | $162.40 K | - |
FAQ
- What is Oncolytics Biotech annual total liabilities?
- What is the all time high annual total liabilities for Oncolytics Biotech?
- What is Oncolytics Biotech annual total liabilities year-on-year change?
- What is Oncolytics Biotech quarterly total liabilities?
- What is the all time high quarterly total liabilities for Oncolytics Biotech?
- What is Oncolytics Biotech quarterly total liabilities year-on-year change?
What is Oncolytics Biotech annual total liabilities?
The current annual total liabilities of ONCY is $8.49 M
What is the all time high annual total liabilities for Oncolytics Biotech?
Oncolytics Biotech all-time high annual total liabilities is $15.13 M
What is Oncolytics Biotech annual total liabilities year-on-year change?
Over the past year, ONCY annual total liabilities has changed by +$504.50 K (+6.32%)
What is Oncolytics Biotech quarterly total liabilities?
The current quarterly total liabilities of ONCY is $11.25 M
What is the all time high quarterly total liabilities for Oncolytics Biotech?
Oncolytics Biotech all-time high quarterly total liabilities is $15.13 M
What is Oncolytics Biotech quarterly total liabilities year-on-year change?
Over the past year, ONCY quarterly total liabilities has changed by -$1.30 M (-10.39%)